Fas Ligand Treatment of Peripheral Blood Cells Reduces Graft Immune Reactivity

Overview

Brief ex vivo treatment of G-CSF-mobilized peripheral blood cells with hexameric Fas ligand using a closed automated system selectively induces apoptosis in donor T-cell subsets and antigen-presenting cells without harming CD34+ stem cells. This process significantly diminishes immune cell reactivity of the graft both in vitro and in vivo, potentially reducing graft-versus-host disease (GvHD) while preserving engraftment and graft-versus-tumor effects.

Background

Allogeneic hematopoietic stem-cell transplantation (HSCT) is a curative therapy for various hematological diseases by replacing diseased host cells. G-CSF-mobilized peripheral blood cells contain T cells that promote engraftment and graft-versus-tumor effects but can also cause graft-versus-host disease (GvHD) by attacking host tissues. Current immunosuppressive strategies to prevent GvHD often impair engraftment and immune reconstitution. Prior studies demonstrated that ex vivo Fas ligand treatment selectively induces apoptosis in harmful immune cells while sparing hematopoietic stem cells, uncoupling GvHD from beneficial graft effects.

Data Highlights

Key Findings

• Brief incubation with hexameric Fas ligand selectively induces apoptosis in donor T-cell subsets and antigen-presenting cells without affecting CD34+ hematopoietic stem cells.
• FasL treatment reduces immune cell reactivity of the graft in vitro and in vivo, potentially lowering the risk of GvHD.
• The closed automated cell processing system enables standardized, reproducible ex vivo FasL treatment of peripheral blood cell products.
• CD34+ cells maintain high viability and expansion potential after FasL treatment, preserving engraftment capacity.
• Glutathione levels in CD34+ cells remain stable post-treatment, indicating preserved cellular redox balance.
• FasL-treated grafts may provide a novel therapeutic approach to prevent rejection and treat immune-mediated conditions such as GvHD, ARDS, and sepsis.

Clinical Implications

Ex vivo Fas ligand treatment of peripheral blood grafts offers a promising strategy to selectively reduce harmful immune cells responsible for GvHD while preserving essential stem cells for engraftment. This approach may improve transplantation outcomes by minimizing immune-mediated complications without compromising graft-versus-tumor effects. The closed automated system facilitates clinical translation by ensuring consistent and safe processing.

Conclusion

Short ex vivo Fas ligand treatment of peripheral blood cell products effectively diminishes graft immune reactivity by selectively targeting deleterious immune cells while sparing hematopoietic stem cells. This method holds potential to improve allogeneic HSCT outcomes and may be applicable to other immune-related conditions.

References

1. Previous study on FasL treatment uncoupling GvHD and GvT -- 9
2. Jeong et al. on glutathione measurement using FreSHTracer -- 17